远程优化射血分数降低心衰患者的指南导向药物治疗
这项病例对照研究纳入1028例HFrEF患者,197例接受由导航员主导的远程算法驱动GDMT优化,831例继续常规治疗。3个月时干预组RAS拮抗剂和β受体阻滞剂使用比例显著增加,而常规组无变化,提示远程滴定可缩小指南与实践差距。
要点
- 远程导航员算法优化使RAS拮抗剂使用从70.1%升至86.3%,β受体阻滞剂从77.2%升至91.9%。
- 干预组各类GDMT剂量也较基线增加,而常规组使用比例和剂量均无变化。
- 远程滴定可能成为快速缩小HFrEF指南与实践差距的人群级策略。
核心结论
- 由导航员使用编码算法远程滴定GDMT可能是一种高效的人群级策略,可快速缩小HFrEF患者指南与临床实践之间的差距。
研究设计与样本
- 病例对照研究,基于人群样本纳入1028例HFrEF患者(平均年龄68岁,平均射血分数32%,女性305例占30.0%,NYHA I-II级892例占86.8%)。
- 197例(19.2%)参与导航员主导的远程药物优化项目,831例(80.8%)继续常规治疗作为对照组。
主要发现
- 3个月时干预组RAS拮抗剂使用从138例(70.1%)增至170例(86.3%),P < .001。
- 3个月时干预组β受体阻滞剂使用从152例(77.2%)增至181例(91.9%),P < .001。
- 3个月时干预组盐皮质激素受体拮抗剂使用从51例(25.9%)增至60例(30.5%),P = .14。
- 干预组各类GDMT剂量较基线增加。
- 常规组GDMT使用比例和各类剂量均无变化。
关键数值与推荐
- 远程优化方案依据当前美国心脏病学会/美国心脏协会心衰指南建模的序贯滴定算法。
- 导航员通过电话联系参与者指导药物调整,并在药师、执业护士和心衰心脏病专家监督下进行实验室检查、血压和症状的纵向监测。
临床怎么用
- 对于HFrEF患者,可考虑由导航员在药师、护士和心衰专科医生监督下,通过远程电话和算法指导GDMT滴定。
- 远程优化可提高RAS拮抗剂和β受体阻滞剂的使用比例及剂量,但对盐皮质激素受体拮抗剂的使用提升有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Optimal treatment of heart failure with reduced ejection fraction (HFrEF) is scripted by treatment guidelines, but many eligible patients do not receive guideline-directed medical therapy (GDMT) in clinical practice. OBJECTIVE: To determine whether a remote, algorithm-driven, navigator-administered medication optimization program could enhance implementation of GDMT in HFrEF. DESIGN, SETTING, AND PARTICIPANTS: In this case-control study, a population-based sample of patients with HFrEF was offered participation in a quality improvement program directed at GDMT optimization. Treating clinicians in a tertiary academic medical center who were caring for patients with heart failure and an ejection fraction of 40% or less (identified through an electronic health record-based search) were approached for permission to adjust medical therapy according to a sequential titration algorithm modeled on the current American College of Cardiology/American Heart Association heart failure guidelines. Navigators contacted participants by telephone to direct medication adjustment and conduct longitudinal surveillance of laboratory tests, blood pressure, and symptoms under supervision of a pharmacist, nurse practitioner, and heart failure cardiologist. Patients and clinicians declining to participate served as a control group. EXPOSURES: Navigator-led remote optimization of GDMT compared with usual care. MAIN OUTCOMES AND MEASURES: Proportion of patients receiving GDMT in the intervention and control groups at 3 months. RESULTS: Of 1028 eligible patients (mean [SD] values: age, 68 [14] years; ejection fraction, 32% [8%]; and systolic blood pressure, 122 [18] mm Hg; 305 women (30.0%); 892 individuals [86.8%] in New York Heart Association class I and II), 197 (19.2%) participated in the medication optimization program, and 831 (80.8%) continued with usual care as directed by their treating clinicians (585 [56.9%] general cardiologists; 443 [43.1%] heart failure specialists). At 3 months, patients participating in the remote intervention experienced significant increases from baseline in use of renin-angiotensin system antagonists (138 [70.1%] to 170 [86.3%]; P < .001) and β-blockers (152 [77.2%] to 181 [91.9%]; P < .001) but not mineralocorticoid receptor antagonists (51 [25.9%] to 60 [30.5%]; P = .14). Doses for each category of GDMT also increased from baseline in the intervention group. Among the usual-care group, there were no changes from baseline in the proportion of patients receiving GDMT or the dose of GDMT in any category. CONCLUSIONS AND RELEVANCE: Remote titration of GDMT by navigators using encoded algorithms may represent an efficient, population-level strategy for rapidly closing the gap between guidelines and clinical practice in patients with HFrEF.
引用
- Desai AS, Maclean T, Blood AJ, et al. Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2020. PMID: 32936209. doi:10.1001/jamacardio.2020.3757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。